4//SEC Filing
ORBIMED ADVISORS LLC 4
Accession 0000947871-25-001085
CIK 0001664710other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:34 PM ET
Size
12.5 KB
Accession
0000947871-25-001085
Insider Transaction Report
Form 4
ORBIMED ADVISORS LLC
Director
Transactions
- Disposition to Issuer
Common Stock
2025-11-21$17.75/sh−140,057$2,486,012→ 759,155 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2025-11-21$17.75/sh−74,465$1,321,754→ 45,057 total(indirect: See footnotes)
OrbiMed Capital GP VII LLC
Director
Transactions
- Disposition to Issuer
Common Stock
2025-11-21$17.75/sh−140,057$2,486,012→ 759,155 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2025-11-21$17.75/sh−74,465$1,321,754→ 45,057 total(indirect: See footnotes)
OrbiMed Genesis GP LLC
Director
Transactions
- Disposition to Issuer
Common Stock
2025-11-21$17.75/sh−140,057$2,486,012→ 759,155 total(indirect: See footnotes) - Disposition to Issuer
Common Stock
2025-11-21$17.75/sh−74,465$1,321,754→ 45,057 total(indirect: See footnotes)
Footnotes (4)
- [F1]Disposed of in connection with the Issuer's completion of a cash tender offer.
- [F2]These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
- [F3]These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
- [F4]This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Keros Therapeutics, Inc.
CIK 0001664710
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001055951
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 4:34 PM ET
- Size
- 12.5 KB